



KANE
BIOTECH

Investor Presentation
Mark Ahrens-Townsend
President & CEO
June 2018

Disclaimer – Forward Looking Statements



This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue R&D activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, and uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's ongoing filings which are available on SEDAR for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements nor does the Company undertake to update or revise any these forward-looking statements contained herein.

Table of Contents

Corporate Overview

- (1) Antimicrobial Resistance Crisis
- (2) Biofilm
- (3) Kane Anti-Biofilm Technology
- (4) Board of Directors & Advisor
- (5) Corporate Strategy & Direction

Animal Health



- (6) Market Strategy & Goals
- (7) Companion Pet Market
- (8) Commercialization Strategy
- (9) StrixNB Oral Care for Veterinary Clinics
- (10) Dechra Partnership
- (11) Bluestem Oral Care

STRIXNB™
A SMARTER WAY TO FIGHT BACTERIA

bluestem™
oral care

Human Health



- (12) Human Health Applications
- (13) Human Dermatology Applications
- (14) Commercial & Industrial Licensing Opportunities
- (15) Food Processing & Preparation
- (16) Biofouling Industrial Applications

Summary

- (17) Summary & Investment Thesis
- (18) Upcoming Milestones
- (19) Financial Performance & Projections

Appendices

- (1) Appendix: Bluestem Oral Care Efficacy Study
- (2) Appendix: Bluestem Oral Care Safety Study
- (3) Appendix: Biofilm Expertise & Differentiation
- (4) Appendix: Most Recent Press Releases

Antimicrobial Resistance Crisis

“Drug Resistance Epidemic!”

“Global Pandemic!”

In 2016 the United Nations declared antibiotic resistance
“the greatest and most urgent global risk”


One of the “*SuperBugs*”, MRSA, kills more Americans each year than HIV/Aids, Parkinson’s disease, emphysema and homicide combined

“Most serious infections occur in health care settings”

- 2 million Americans develop Hospital Acquired Infections (HAIs) every year, resulting in 99,000 deaths, most due to antibiotic resistant pathogens
- Intensive Care Unit mortality rates climbing

Authorities estimate the current annual worldwide death toll due to antibiotic resistance at 700,000


By 2050, an estimated 10 million people will die every year due to antimicrobial resistance (AMR) unless a global response to AMR is mounted



“Biofilm” is what Kane is all about

- **Biofilms:** Higher order structures (“Fortresses”) that bacteria and fungi use to protect themselves

These formed matrixes attach and grow on living and inert surfaces becoming up to 1000x more resistant to antibiotics, biocides and disinfectants



SEM image of an MRSA biofilm

Chronic wounds alone cost the US health care system


\$20B
annually

Involved in
80%
of animal & human
bacterial infections



Tooth decay
Inflammatory skin disorders
Hospital-acquired infections (HAIs)
Chronic wounds
Foodborne Outbreaks

Kane Anti-Biofilm Technology

BIOFILM
INHIBITION



BIOFILM
DISPERSAL



Board of Directors & Advisor



Mark Ahrens-Townsend | Chief Executive Officer & Director

Mark Ahrens-Townsend joined Kane Biotech in May 2015 as President and CEO. Mr. Ahrens-Townsend brings extensive expertise in leadership, strategic planning, and business development. He has spent 30+ years in the Technology, Engineering and Venture Capital industries. For over 20 years Mr. Ahrens-Townsend has held senior executive roles, twice previously as President and CEO of two publicly traded technology companies, and has also served extensively on the boards and committees of several private and publicly held companies. Mr. Ahrens-Townsend holds B.Sc. (Engineering) and MBA (Finance) degrees from the University of Manitoba.



Philip Renaud | Chairman

Mr. Renaud is Managing Director of Church Advisors, a European investment advisory firm involved in private financings. A graduate of Franklin College of Switzerland with a Bachelor of Arts in international financial management, Mr. Renaud has been instrumental in securing many private equity financings and has an extensive European and North American network. He is a director of a number of publicly traded companies including Yorbeau Resources Inc., Diagnos Inc., Sierra Metals Inc., and is on the advisory board of Dundee Sarea.



Mark Nawacki | Director

Mr. Mark Nawacki is the president and CEO of Searchlight Pharma. Prior to this, Mr. Nawacki served as Executive Vice President, Business and Corporate Development of Paladin Labs, a leading Canadian specialty pharmaceutical company, from 2003 – 2014. Mr. Nawacki holds a BA in International Relations and Russian and East European Studies from the University of Toronto (Trinity), MBA also from there, and is a Canadian-designated CPA.



Marc Edwards | Director

Mr. Edwards is the founder and President of VetRx, a Montreal-based technology company specializing in data collection, cleansing, marketing and pharmaceutical compliance for the veterinary industry. Mr. Edwards holds a Bachelor's degree (Finance) from l'Université de Sherbrooke and an MBA from Concordia University.



Rasheida (Rivka) Gluck | Director

Ms. Gluck is Senior VP of Global Clinical Operations at Aurinia Pharmaceuticals Inc. She was previously VP of Clinical Operations at Qu Biologics Inc. and was responsible for leading their clinical programs and providing strategic direction for the clinical development of their platform immunotherapeutic treatments in multiple disease indications. Prior to that, Ms. Gluck was VP of Clinical Operations at Aspreva responsible for the successful integration of the global clinical operations department post acquisition by Zurich-based Vifor Pharmaceuticals. At Vifor, she was VP and Head of Global Clinical Operations where she was a member of the Research, Development, and Leadership team and continued to build and lead the clinical research department in Zurich and hold overall accountability for the execution and delivery of all global clinical programs. Ms. Gluck served in increasingly senior positions at major pharmaceutical companies including Novartis, Organon, and GSK. Ms. Gluck holds a B.Sc. in Nursing from the University of British Columbia.



Sarah Prichard, M.D. | Advisor

Dr. Sarah Prichard has served as global Vice President of R&D, Renal Medical and Therapeutic Area Leader, Baxter Healthcare from 2005-2014. Her responsibilities included developing Baxter's strategies for the commercialization of new renal business products, global medical affairs and clinical development. Prior to this role, she was on faculty at McGill University from 1979-2005. Dr. Prichard received her MD from Queens University and trained in Internal Medicine and Nephrology at McGill University. At McGill, she was Professor of Medicine and served as Associate Dean of Medicine, Chief of Service for the Department of Medicine, Director of Peritoneal Dialysis at the Royal Victoria Hospital and President of the Canadian Society of Nephrology.




Corporate Strategy & Direction



- ✓ **Animal Health**
- ✓ **Human Health**
- ✓ **Food Processing**
- ✓ **Food Preparation**
- ✓ **Industrial Applications**
- ✓ **Biofouling**

- Biotechnology company engaged in research, development and commercialization of technologies that **inhibit and disperse biofilms**
- **Royalty-based Revenue Model**
 - through Licensing and Global Partnerships
- Rich Intellectual Property Portfolio
 - Including **75 patents & patents pending**
- **Strong Management & Board**
 - Formed in 2001 and leading the charge in biofilm R&D and commercialization

A photograph of a smiling woman with blonde hair holding a small, fluffy brown and white dog. The dog has its tongue hanging out and is looking towards the camera. The background is a blurred outdoor setting with trees and a path, suggesting a park or a field. The image is framed by dark teal bars at the top and bottom.

Animal Health Applications

Market Strategy & Goals

First, enter companion pet health market

- Why?
 - Size and growth
 - Relative ease of regulatory path
 - Lack of certified products with quality and efficacy differentiated by science and patent protection
- Expand to other markets
 - Animal and human health applications
 - Commercial, institutional and industrial applications



Companion Pet Market

\$69 Billion in U.S. for 2017 & growing 5% – 7% annually

80 million homes

in the U.S. have a cat or dog or both

Kane's current target markets:

– Oral health (\$1.5 Billion worldwide)

Toothpaste, water additives, oral spray, treat, wipe, foam, gel and rawhide chew

– Skincare / dermatology (>\$2 Billion worldwide)

1. Ear infections (otic drops)
2. Wounds and skin “hot spots” infections
3. Atopic dermatitis shampoo

(Zoetis products - APOQUEL® & CYTOPOINT® revenue ~\$600 million USD in 2018)

Channels of market access:

1. Veterinary clinics
2. Pet specialty retail stores (major chains and distributors)
3. Grocery / mass (Walmart, Costco, ...)
4. Internet e-commerce

Commercialization Strategy



Step 1 - Canada used as a Test Market for Animal Health

- ✓ Products based on science, safety, efficacy & value
- ✓ Branding, premium packaging & positioning, advertising, vet endorsements

Step 2 - Conclude Market Access Partner

- ✓ 10+ year royalty model deal signed with major player

Step 3 - Geographic Expansion with Partner

- Europe, Asia, ROW
- Discussions in progress

Step 4 - Conclude Additional Partner(s) for Pet Specialty & Grocery / Mass Retailers

- Discussions in progress

StrixNB™ Oral Care for Veterinary Clinics **KANE** BIOTECH

- Premium brand
 - Science
 - Safety
 - Efficacy
 - Value
- Initial products:
 - Water additive
 - Liquid
 - Powder
 - Oral spray
 - Toothpaste
- Launched in Canada by Kane
- Licensed to Dechra Veterinary Products LLC in 2017 for N.A.



Vetradent™ Oral Care

KANE
BIOTECH

- Introducing VETRADENT

- From



- U.S. & Canada launch:
 - Q4 2017

- Products coming:

- Wipe ✓
- Dental treat
- Rawhide chew



Kane - Dechra Agreement



- **10+ year exclusive License & Distribution**
- **North American veterinary market only**
- **Incorporates two Kane Biotech technologies**
 1. StrixNB™ for companion pet oral care applications
 2. DispersinB® for dermatology applications
- **\$500,000 USD on signing**
 - Commercial milestones to max \$2 million USD
 - Ongoing royalties, subject to minimums
- **Vetradent launched Q4 2017**
- **DispersinB® otic drops: Targeted Q3 2018**

Bluestem Oral Care

KANE
BIOTECH

bluestem clinically tested pet care products

Oral health care has gone to the dogs.
COME
It's about time.

Without an oral care routine, chances are your dog will face periodontal disease at some point, and probably within her first five years.

[learn more](#)

There's a better way to rinse for good oral health

bluestem with coactive technology

- Helps fight plaque and tartar and bad breath
- Scientifically formulated with food-grade ingredients
- Clinically proven safe and effective for every day use

bluestem

• Sulfate Free • Alcohol Free • Artificially Flavored Free

- Sold in 895 pet specialty stores + Amazon
- Actively looking for market access partners



Human Health Applications



Human Dermatology Applications



Athlete's Foot (Tinea Pedis)

- Afflicts 15% of world population
- \$881mm global market, \$994mm in 2021
- High growth rate, lack of innovation
- Potential partners/competitors: Bayer, Novartis, Blaine Labs

Atopic Dermatitis (Eczema)

- Afflicts 10% (adult) - 25% (child) of world population
- \$5.6B global market by 2022
- Potential partners/competitors: J&J, L'Oreal, SkinMedix, Galderma, Bioderma

Seborrheic Dermatitis (& Chronic Dandruff)

- \$6B global market by 2020
- Fastest growing hair care segment (Asian market \$2.4B)
- Potential partners/competitors: P&G, J&J, Sanofi

KANE SHAMPOO TESTIMONIAL:

“For the 1st time in decades, this person shows NO signs of dandruff and seborrheic dermatitis at all. NONE! I would characterize this result as miraculous! This person has literally tried any and all products including prescription medications. This product you have developed is a GAMECHANGER. We are blown away by the results.”

– Managing Director, Large Investment Banking Firm

MARKET OPPORTUNITY:

“If your human shampoo works well, I think it could easily be a \$100 MM product.”

– Managing Director, US based Asset Management Capital Partners LLC


Kane Biotech Granted U.S. Wound Care Patent



WINNIPEG, Manitoba, (GlobeNewswire May 31, 2018) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF) (the “Corporation” or “Kane Biotech”) is pleased to announce it has been granted a significant patent in the area of wound care by the U.S. Patent and Trademark Office (the “USPTO”). The patent is titled “Antimicrobial-Antibiofilm Compositions And Methods Of Use Thereof”. The abstract released by the USPTO states, “Compositions comprising chelating agents, metal ion salts, gelling agents or a buffer, antimicrobials, antibiofilm agents, and a pH adjuster or a buffer for the prevention and treatment of wound infections and food-borne diseases involving bacterial biofilms are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive wound infection associated bacteria occurring in polymicrobial biofilms. The composition may be in the form of lotion, cream, ointment, dressing, bandage, rinse, soak, gel, spray or other suitable forms, including certain devices. Additionally, the invention offers an efficient method of delivering the formulated composition containing one or more chelating agents in combination with a metal ion salt using either a nanoparticle or other efficient delivery systems.”

Mark Ahrens-Townsend, President and CEO commented “Granting of this patent by the USPTO is significant in Kane Biotech’s “Strix Wound Care” technology family and is the basis for treatment applications the Corporation is developing for chronic inflammatory skin disorders including, among other diseases and applications, athlete’s foot, atopic dermatitis (eczema), and seborrheic dermatitis (often associated with chronic dandruff). We’re pleased to have this intellectual property added to Kane Biotech’s portfolio of 75 patents and patents pending.”

Following the issuance of this Press Release, the halt trading order of Kane Biotech’s stock on the TSX Venture Exchange will be lifted and trading resumed.

A modern conference room with large windows, a projector, and several office chairs. The room is brightly lit by natural light from the windows. A projector is mounted on the ceiling. The floor is covered with a patterned carpet. The text "Commercial & Industrial Licensing Opportunities" is overlaid on a teal banner in the center of the image.

Commercial & Industrial Licensing Opportunities

Food Processing & Preparation

- Listeria causes **1600** serious infections per year and around **260** fatalities in the U.S.

~30%

of floors and drains sampled in a 2004 study tested positive for Listeria

- **Biofilms** are the main cause of contamination



The U.S. Department of Agriculture (USDA) estimates the costs associated with food borne illness to be \$5.5 to \$22 Billion a year

Biofouling Industrial Applications

- ✓ Chemical and petroleum industries
- ✓ Water treatment plants

\$42.9 billion

Global industrial & institutional
cleaning chemicals market in 2017



Summary & Investment Thesis



Specialized focus on large markets for biofilm prevention and dispersion solutions


- **Strong patent portfolio of biofilm dispersion technologies**
 - 75 patents and patents pending
- **1st Commercial licensing & distribution agreement signed**
 - 10 year agreement with Dechra for North American veterinary market only
 - Further expansion and additional licensing partners being pursued
- **Potential for several antibiofilm applications in development for large market opportunities**
 - Human and animal health products for dermatology & wound care applications
 - Hard surface disinfectant for health care institution & home applications
 - Food processing & preparation / Biofouling

Financial Performance & Projections



Kane Biotech Inc.	Actuals				Budget
TSX-V:KNE / OTCQB:KNBIF (\$000s)	2014	2015	2016	2017	2018
Total Revenues	\$42	\$226	\$380	\$1,035	\$2,901
Total Expenses	\$1,637	\$1,891	\$2,690	\$3,682	\$4,561
Loss	-\$1,615	-\$1,710	-\$2,549	-\$2,786	-\$2,054

Since 2014 Kane's revenue has grown at an average annual growth rate of 228%, exceeding \$1 million dollars CDN in 2017.



Upcoming Milestones

- Uplist to OTCQB Venture Market
- Retain Investor Relations Counsel
- File lawsuit against Nestlé to defend Kane Biotech's intellectual property
- Launch 1st DispersinB[®] based product [Q2-Q3]
- Existing license expansion [Q2-Q3]
 - Geography
 - Product applications
- Achieve international standard of efficacy [Q3-Q4]
- Execute new license agreements [Q3-Q4]
- Initiate clinical trials for technologies treating human chronic inflammatory skin disorders [Q3-Q4]



Investor Relations

Mark Ahrens-Townsend, President and CEO

1-204.477.7592

ir@kanebiotech.com

Tirth Patel, VP Investor Relations

1-646-653-7035

tpatel@edisongroup.com

Stock Symbols: TSX-V:KNE OTCQB:KNBIF

www.kanebiotech.com


Bluestem Oral Care - Efficacy

Canine Efficacy Study Results

- 84 day study
- 60 dogs
 - 30 control group, 30 StrixNB

Calculus Reduction

- Day 28 – 14%
- Day 56 – 23%*
- Day 84 – 25%*



*Statistically Significant

Bluestem Oral Care - Safety



Canine Safety Study

30 day study

6 beagle dogs in each treatment group

Treatment Groups:

Group One-Controlled (Tap Water)

Group Two- Recommended Dose of bluestem

Group Three- Five Times Recommended Dose of bluestem



Bluestem Oral Care - Safety

Results:

Clinical observations, physical observation, and oral assessment revealed **no evidence of adverse effects related to consumption of the water additive.** This study demonstrated the safety of Bluestem Water Additive at 1 and 5 times the recommended dose for 30 consecutive days.



Bluestem Oral Care - Safety

What is LRVHP?



- LRVHP stands for Low Risk Veterinary Health Products. Health Canada established safety guidelines to help consumers choose safer products.
- bluestem products have the LRVHP notification number, meaning they comply with Health Canada's safety standards
- Xylitol-Free
- Alcohol-Free
- Chlorhexidine-Free
- Green Tea Extract-Free

Biofilm Expertise & Differentiation



Biofilm science is a relatively new technical discipline that has emerged in response to the tremendous opportunities and significant costs resulting from damage caused by biofilms. It was not until the 1990s that the elaborate organization of attached bacteria was appreciated and that these structures exhibited a mode of growth that allowed survival in hostile environments, causing multidisciplinary problems.

With a small team of scientists in microbiology and molecular biology, Kane Biotech was formed in 2001 to study the genetic mechanisms of biofilm formation, which has led to the discovery of novel compounds that inhibit or disrupt biofilms.

With 75 patents and patents pending, Kane Biotech has become a world leader in biofilm intellectual property, protected technologies based on molecular mechanisms of biofilm formation & dispersal, & methods for finding components that inhibit or disrupt biofilms.

It is just within the last 2-3 years that Kane Biotech has added the resources to start commercializing its technologies.

Kane Biotech Granted U.S. Wound Care Patent



WINNIPEG, Manitoba, (GlobeNewswire May 31, 2018) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF) (the “Corporation” or “Kane Biotech”) is pleased to announce it has been granted a significant patent in the area of wound care by the U.S. Patent and Trademark Office (the “USPTO”). The patent is titled “Antimicrobial-Antibiofilm Compositions And Methods Of Use Thereof”. The abstract released by the USPTO states, “Compositions comprising chelating agents, metal ion salts, gelling agents or a buffer, antimicrobials, antibiofilm agents, and a pH adjuster or a buffer for the prevention and treatment of wound infections and food-borne diseases involving bacterial biofilms are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive wound infection associated bacteria occurring in polymicrobial biofilms. The composition may be in the form of lotion, cream, ointment, dressing, bandage, rinse, soak, gel, spray or other suitable forms, including certain devices. Additionally, the invention offers an efficient method of delivering the formulated composition containing one or more chelating agents in combination with a metal ion salt using either a nanoparticle or other efficient delivery systems.”

Mark Ahrens-Townsend, President and CEO commented “Granting of this patent by the USPTO is significant in Kane Biotech’s “Strix Wound Care” technology family and is the basis for treatment applications the Corporation is developing for chronic inflammatory skin disorders including, among other diseases and applications, athlete’s foot, atopic dermatitis (eczema), and seborrheic dermatitis (often associated with chronic dandruff). We’re pleased to have this intellectual property added to Kane Biotech’s portfolio of 75 patents and patents pending.”

Following the issuance of this Press Release, the halt trading order of Kane Biotech’s stock on the TSX Venture Exchange will be lifted and trading resumed.

Kane Biotech – 2017 Year End & Fourth Quarter Financial Results and Business Update



WINNIPEG, Manitoba – (GlobeNewswire – March 21, 2018) – Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF) (the “Corporation” or “Kane Biotech”) is pleased to announce its 2017 Year End and Fourth Quarter Financial Results.

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms are thin slimy films that develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. Biofilms attach to and grow on living and inert surfaces. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides and host immune responses. This resiliency contributes to numerous human and animal health related problems. According to the United States National Institutes of Health, biofilms are estimated to be responsible for 80% of all animal and human bacterial infections including tooth decay, wound care infections, chronic inflammatory skin disorders and wounds, recurrent urinary tract infections, medical device associated and hospital acquired infections (HAIs), and foodborne bacterial outbreaks. Biofilms cost society billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech’s mission is to be a royalty-based revenue company licensing its anti-biofilm technologies to global industry players.

Key Highlights of Kane Biotech include the following: ...

Kane Biotech Sues Nestlé



WINNIPEG, Manitoba – (GlobeNewswire – February 26, 2018) – Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) today announced that it has filed a lawsuit against Nestec, Ltd., a/k/a Nestec, S.A. (“Nestec”), and Nestlé Purina Petcare Global Resources, Inc. (“Nestlé Purina”), (collectively “Nestlé”) for breach of agreements between the parties, and misappropriation of Kane Biotech’s trade secrets and intellectual property. In the six-count complaint filed under seal in U.S. federal court in Missouri, Kane Biotech alleges, amongst other improper activities, that a Nestlé patent application makes improper use of Kane Biotech’s patent rights for oral care, personal care and wound care antimicrobial and anti-biofilm technologies that the Corporation developed.

Mark Ahrens-Townsend, President & CEO of Kane Biotech, said, “Kane Biotech has invested significantly in its intellectual property and it will vigorously protect and defend its interests and the interests of its shareholders against anyone who seeks to profit from it without proper compensation to our Corporation.”